Rafael Amado - 04 Mar 2026 Form 4 Insider Report for Zai Lab Ltd (ZLAB)

Role
President, Head of Global Oncology Research and Development
Signature
/s/ Bruce Blefeld, Attorney-in-Fact
Issuer symbol
ZLAB
Transactions as of
04 Mar 2026
Net transactions value
-$55,083
Form type
4
Filing time
16 Mar 2026, 16:07:59 UTC
Previous filing
05 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Amado Rafael President, Head of Global Oncology Research and Development C/O ZAI LAB LIMITED, 314 MAIN STREET, 4TH FLOOR, SUITE 100, CAMBRIDGE /s/ Bruce Blefeld, Attorney-in-Fact 16 Mar 2026 0001662119

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZLAB American Depositary Shares Options Exercise +5,323 +13% 47,714 12 Mar 2026 Direct F1, F2, F3
transaction ZLAB American Depositary Shares Sale $55,083 -2,957 -6.2% $18.63 44,757 13 Mar 2026 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZLAB Stock Options (Right to Buy) Award +103,950 $0.000000* 103,950 04 Mar 2026 American Depositary Shares 103,950 $19.27 Direct F1, F5
transaction ZLAB Restricted Share Units Award +33,783 $0.000000* 33,783 04 Mar 2026 American Depositary Shares 33,783 Direct F1, F3, F6
transaction ZLAB Restricted Share Units Options Exercise -5,323 -25% $0.000000* 15,971 12 Mar 2026 American Depositary Shares 5,323 Direct F1, F3, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share ("ADS") represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
F2 ADSs acquired upon vesting of Restricted Share Units ("RSUs").
F3 Each RSU represents a contingent right to receive one ADS.
F4 These ADSs were sold automatically to cover taxes upon vesting of RSUs.
F5 The option vests in equal annual installments over four years beginning on 03/04/2027, the first anniversary of the date of grant, subject to continuous service.
F6 The RSUs vest in equal annual installments over four years beginning on 03/04/2027, the first anniversary of the date of grant, subject to continuous service. Vested shares will be delivered in the form of ADSs to the reporting person following vesting.
F7 The RSUs vest in equal annual installments over four years beginning on 03/12/2026, the first anniversary of the date of grant, subject to continuous service. Vested shares will be delivered in the form of ADSs to the reporting person following vesting.

Remarks:

President, Head of Global Oncology Research and Development